Last $72.69 USD
Change Today +2.23 / 3.17%
Volume 381.7K
PTCT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:58 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

ptc therapeutics inc (PTCT) Snapshot

Open
$71.56
Previous Close
$70.46
Day High
$73.30
Day Low
$71.56
52 Week High
02/27/15 - $75.94
52 Week Low
05/21/14 - $14.51
Market Cap
2.4B
Average Volume 10 Days
1.1M
EPS TTM
$-3.21
Shares Outstanding
33.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PTC THERAPEUTICS INC (PTCT)

ptc therapeutics inc (PTCT) Related Bloomberg News

View More Bloomberg News

ptc therapeutics inc (PTCT) Details

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, as well as develops spinal muscular atrophy, which is in Phase II clinical program. The company’s preclinical development programs include PTC596, a development candidate used for the treatment of chemotherapy resistant cancers; and PTC672, an antibacterial development candidate for the treatment of life-threatening infections caused by multidrug-resistant Gram-negative bacteria. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program. The company was founded in 1998 and is based in South Plainfield, New Jersey.

187 Employees
Last Reported Date: 03/2/15
Founded in 1998

ptc therapeutics inc (PTCT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Execu...
Total Annual Compensation: $460.8K
Chief Commercial Officer
Total Annual Compensation: $368.2K
Compensation as of Fiscal Year 2013.

ptc therapeutics inc (PTCT) Key Developments

PTC Therapeutics Announces Translarna™ Access Program in Duchenne Muscular Dystrophy for Siblings of Patients Participating in PTC Clinical Trials

PTC Therapeutics, Inc. announced that it will make Translarna available for siblings of patients in certain open label PTC clinical trials for nonsense mutation Duchenne muscular dystrophy (nmDMD). Translarna will be made available to these siblings in advance of commercial availability in their regions, after a treating physician and the patient or guardian make a clinical decision to use Translarna, and consistent with any other applicable regulatory requirements. Translarna, discovered and developed by PTC Therapeutics, Inc., is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as dystrophin in Duchenne muscular dystrophy. Translarna is licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. Translarna is an investigational new drug in the United States. The development of Translarna has been supported by grants from Cystic Fibrosis Foundation Therapeutics Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); Muscular Dystrophy Association; FDA'sOffice of Orphan Products Development; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy.

PTC Therapeutics, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Financial Guidance for the Full Year 2015

PTC Therapeutics, Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss and net loss attributable to common shareholders of $27,269,000 or $0.84 per basic and diluted share on total revenues of $12,658,000 against net loss and net loss attributable to common shareholders of $17,885,000 or $0.75 per basic and diluted share on total revenues of $4,411,000 a year ago. Loss from operations of $32,230,000 and loss from operations before tax benefit of $31,962,000 against loss from operations of $18,092,000 and loss from operations before tax benefit of $17,885,000 a year ago. For the full year, the company reported net loss and net loss attributable to common shareholders of $93,753,000 or $2.97 per basic and diluted share on total revenues of $25,245,000 against net loss and net loss attributable to common shareholders of $51,574,000 or $5.18 per basic and diluted share on total revenues of $34,696,000 a year ago. Loss from operations of $99,413,000 and loss from operations before tax benefit of $98,446,000 against loss from operations of $45,398,000 and loss from operations before tax benefit of $51,574,000 a year ago. Operating expense for the full year 2015 is anticipated to be between $160- $170 million, excluding expected non-cash stock-based compensation expense of approximately $30 million, for total operating expenses of approximately $190 million to $200 million. These expenses will be primarily in support of its ongoing and planned confirmatory Phase 3 clinical trials for Translarna in nmDMD and nmCF, commercial launch activities for Translarna in the EU as well as pre-commercial activities in the US, and the continued research and clinical development of other product pipeline candidates.

Investors Reportedly Eyes Stake In PTCT

PTC Therapeutics, Inc. (NasdaqGS:PTCT) is exploring a potential sale amid takeover interest from Shire plc (LSE:SHP) and BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), according to people familiar with the matter. PTCT is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private. Representatives for could not be reached for comment. Representatives for Shire and BioMarin declined to comment. Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTCT:US $72.69 USD +2.23

PTCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTCT.
View Industry Companies
 

Industry Analysis

PTCT

Industry Average

Valuation PTCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 88.3x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 79.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PTC THERAPEUTICS INC, please visit www.ptcbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.